Skip to main content

Table 2 Effect of SFC therapy on lung function and quality of life in COPD patients

From: Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4+CD25+Foxp3+regulatory T cells in COPD

 

Baseline

SFC therapy

Pre-FEV1 (%)

39.62 ± 2.35

46.10 ± 3.58*

Pre-FEV1 (L)

1.02 ± 0.07

1.15 ± 0.13

Post-FEV1(%)

45.62 ± 2.63

49.00 ± 3.22

Post-FEV1 (L)

1.16 ± 0.08

1.27 ± 0.11

FVC (L)

3.19 ± 0.19

3.25 ± 0.22

FEV1/FVC (%)

36.76 ± 2.02

39.71 ± 2.65

Mean reversibility (%)

Mean reversibility (L)

14.05 ± 2.91

0.15 ± 0.03

8.19 ± 1.96

0.08 ± 0.02*

MMRC dyspnea scale

2.24 ± 0.10

1.33 ± 0.11***

6-min walk test (m)

329.52 ± 8.82

367.14 ± 7.99***

  1. * p < 0.05, *** P < 0.001